You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 10, 2024

CETROTIDE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Cetrotide, and what generic alternatives are available?

Cetrotide is a drug marketed by Emd Serono Inc and is included in one NDA.

The generic ingredient in CETROTIDE is cetrorelix acetate. There is one drug master file entry for this compound. Seven suppliers are listed for this compound. Additional details are available on the cetrorelix acetate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Cetrotide

A generic version of CETROTIDE was approved as cetrorelix acetate by TEVA PHARMS INC on August 12th, 2022.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for CETROTIDE?
  • What are the global sales for CETROTIDE?
  • What is Average Wholesale Price for CETROTIDE?
Summary for CETROTIDE
Drug patent expirations by year for CETROTIDE
Drug Prices for CETROTIDE

See drug prices for CETROTIDE

Recent Clinical Trials for CETROTIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Beni-Suef UniversityPhase 2/Phase 3
Bezmialem Vakif UniversityN/A
Zagazig UniversityN/A

See all CETROTIDE clinical trials

US Patents and Regulatory Information for CETROTIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Emd Serono Inc CETROTIDE cetrorelix acetate POWDER;SUBCUTANEOUS 021197-001 Aug 11, 2000 AP RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Emd Serono Inc CETROTIDE cetrorelix acetate POWDER;SUBCUTANEOUS 021197-002 Aug 11, 2000 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for CETROTIDE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Emd Serono Inc CETROTIDE cetrorelix acetate POWDER;SUBCUTANEOUS 021197-002 Aug 11, 2000 ⤷  Sign Up ⤷  Sign Up
Emd Serono Inc CETROTIDE cetrorelix acetate POWDER;SUBCUTANEOUS 021197-001 Aug 11, 2000 ⤷  Sign Up ⤷  Sign Up
Emd Serono Inc CETROTIDE cetrorelix acetate POWDER;SUBCUTANEOUS 021197-002 Aug 11, 2000 ⤷  Sign Up ⤷  Sign Up
Emd Serono Inc CETROTIDE cetrorelix acetate POWDER;SUBCUTANEOUS 021197-002 Aug 11, 2000 ⤷  Sign Up ⤷  Sign Up
Emd Serono Inc CETROTIDE cetrorelix acetate POWDER;SUBCUTANEOUS 021197-002 Aug 11, 2000 ⤷  Sign Up ⤷  Sign Up
Emd Serono Inc CETROTIDE cetrorelix acetate POWDER;SUBCUTANEOUS 021197-001 Aug 11, 2000 ⤷  Sign Up ⤷  Sign Up
Emd Serono Inc CETROTIDE cetrorelix acetate POWDER;SUBCUTANEOUS 021197-002 Aug 11, 2000 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for CETROTIDE

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Merck Europe B.V. Cetrotide cetrorelix EMEA/H/C/000233
Prevention of premature ovulation in patients undergoing a controlled ovarian stimulation, followed by oocyte-pick-up and assisted-reproductive techniques.In clinical trials, Cetrotide was used with human menopausal gonadotropin (HMG), however, limited experience with recombinant follicule-stimulating hormone (FSH) suggested similar efficacy.
Authorised no no no 1999-04-12
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for CETROTIDE

See the table below for patents covering CETROTIDE around the world.

Country Patent Number Title Estimated Expiration
Hong Kong 21194 LHRH ANTAGONISTS,THEIR MANUFACTURE AND PHARMACEUTICAL COMPOSITIONS THEREOF ⤷  Sign Up
World Intellectual Property Organization (WIPO) 9955357 ⤷  Sign Up
Hungary T67117 ⤷  Sign Up
Czech Republic 9400312 ⤷  Sign Up
Japan 4033919 ⤷  Sign Up
Australia 671881 ⤷  Sign Up
Portugal 87998 PROCESSO PARA A PREPARACAO DE PEPTIDOS ANTAGONISTAS DA HORMONA DE LIBERTACAO DA HORMONA LUTEINIZANTE E DE COMPOSICOES FARMACEUTICAS QUE OS CONTEM ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for CETROTIDE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0299402 C990029 Netherlands ⤷  Sign Up PRODUCT NAME: CETRORELIX, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAAR DBAAR ZUUR ADDITIEZOUT, IN HET BIJZONDER CETRORELIX ACETAAT; REGISTRATION NO/DATE: EU/1/99/100/001-003 19990413
0299402 31/1999 Austria ⤷  Sign Up PRODUCT NAME: CETRORELIX UND PHARMAZEUTISCH ANNEHMBARE SAEUREADDITIONSSALZE DAVON, INSBESONDERE CETRORELIXACETAT; REGISTRATION NO/DATE: EU/1/99/100/001- EU/1/99/100/003 19990413
0299402 099C0031 Belgium ⤷  Sign Up PRODUCT NAME: ACETATE DE CETRORELIX; REGISTRATION NO/DATE: EU/1/99/100/001 19990413
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.